新型冠状病毒疫情时期的慢性阻塞性肺疾病管理策略——2022版慢性阻塞性肺疾病全球倡议解读

摘要/Abstract

中图分类号:

R562

孙娴雯, 李庆云. 新型冠状病毒疫情时期的慢性阻塞性肺疾病管理策略——2022版慢性阻塞性肺疾病全球倡议解读[J]. 诊断学理论与实践, 2022, 21(01): 32-37.

参考文献37

[1]	Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease[R/OL]. [2021-12-28]. https://goldcopd.org/2022-gold-reports/.
[2]	中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第八版修订版)[J]. 中华临床感染病杂志, 2021, 14(2):81-88.
	State Health Commission of the people′s Republic of China. Diagnosis and treatment plan for novel coronavirus pneumonia (trial version of the eighth Revision)[J]. Chin J Clinic Infect Dis, 2021, 14(2):81-88.
[3]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 新型冠状病毒肺炎疫情期间慢性阻塞性肺疾病医疗和防范须知[J]. 中华结核和呼吸杂志, 2020, 43(5):421-426.
	Chronic obstructive pulmonary disease group of respiratory branch of Chinese Medical Association, working committee of chronic obstructive pulmonary disease of respiratory branch of Chinese Medical Association. Notes on medical treatment and prevention of chronic obstructive pulmonary disease during the outbreak of novel coronavirus pneumonia[J]. Chin J Tubercul Respir, 2020, 43(5):421-426.
[4]	Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor[J]. Cell. 2020 Apr 16; 181(2):271-280. doi:S0092-8674(20)30229-4pmid:32142651
[5]	Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study[J]. BMJ, 2020, 369:m1985.
[6]	Milne S, Li X, Yang CX, et al. Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial[J]. Eur Respir J, 2021, 58(1):2100130.
[7]	Streeck H, Schulte B, Kümmerer BM, et al. Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany[J]. Nat Commun, 2020, 11(1):5829. doi:10.1038/s41467-020-19509-y URL
[8]	de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study[J]. Lancet Infect Dis, 2020, 20(9):1034-1042. doi:S1473-3099(20)30371-6pmid:32422204
[9]	Aveyard P, Gao M, Lindson N, et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study[J]. Lancet Respir Med, 2021, 9(8):909-923. doi:10.1016/S2213-2600(21)00095-3pmid:33812494
[10]	Reyes FM, Hache-Marliere M, Karamanis D, et al. Assessment of the Association of COPD and Asthma with In-Hospital Mortality in Patients with COVID-19. A Systematic Review, Meta-Analysis, and Meta-Regression Analysis[J]. J Clin Med, 2021, 10(10):2087. doi:10.3390/jcm10102087 URL
[11]	Press VG, Gershon AS, Sciurba FC, et al. Concerns About Coronavirus Disease-Related Collateral Damage for Patients With COPD[J]. Chest, 2020, 158(3):866-868. doi:10.1016/j.chest.2020.05.549 URL
[12]	Munblit D, Bobkova P, Spiridonova E, et al. Incidence and risk factors for persistent symptoms in adults pre-viously hospitalized for COVID-19[J]. Clin Exp Allergy, 2021, 51(9):1107-1120. doi:10.1111/cea.13997pmid:34351016
[13]	Kyung SY, Kim Y, Hwang H, et al. Risks of N95 Face Mask Use in Subjects With COPD[J]. Respir Care, 2020, 65(5):658-664. doi:10.4187/respcare.06713 URL
[14]	Samannan R, Holt G, Calderon-Candelario R, et al. Effect of Face Masks on Gas Exchange in Healthy Persons and Patients with Chronic Obstructive Pulmonary Disease[J]. Ann Am Thorac Soc, 2021, 18(3):541-544. doi:10.1513/AnnalsATS.202007-812RL URL
[15]	Halperin SA, Ye L, MacKinnon-Cameron D, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial[J]. Lancet, 2022, 399(10321):237-248. doi:10.1016/S0140-6736(21)02753-7 URL
[16]	国家卫生健康委员会疾病预防控制局. 新冠病毒疫苗接种技术指南(第一版)[J]. 中国病毒病杂志, 2021, 11(3):161-162.
	Bureau of disease prevention and control,National Health Commission. Technical guidelines for vaccination against novel coronavirus (First Edition)[J]. Chin J Viral Dis, 2021, 11(3):161-162.
[17]	中国医师协会呼吸医师分会肺功能与临床呼吸生理工作委员会, 中华医学会呼吸病学分会呼吸治疗学组肺功能专业组. 新型冠状病毒肺炎疫情防控期间开展肺功能检查的专家共识[J]. 中华结核和呼吸杂志, 2020, 43(4):302-307.
	Pulmonary function and clinical respiratory physiology Working Committee of respiratory physician branch of Chinese Medical Association, Respiratory therapy group and pulmonary function professional group of respiratory disease branch of Chinese Medical Association. Expert consensus on lung function examination during the prevention and control of novel coronavirus pneumonia[J]. Chin J Tubercul Respir, 2020, 43(4):302-307.
[18]	Bhatt SP, Bodduluri S, Raghav V, et al. The Peak Index: Spirometry Metric for Airflow Obstruction Severity and Heterogeneity[J]. Ann Am Thorac Soc, 2019, 16(8):982-989. doi:10.1513/AnnalsATS.201811-812OC URL
[19]	Ji C, Xia Y, Dai H, et al. Reference values and related factors for peak expiratory flow in middle-aged and elderly Chinese[J]. Front Public Health, 2021, 9:706524. doi:10.3389/fpubh.2021.706524 URL
[20]	Cen J, Ma H, Chen Z, et al. Monitoring peak expiratory flow could predict COPD exacerbations: A prospective observational study[J]. Respir Med, 2019, 148:43-48. doi:10.1016/j.rmed.2019.01.010 URL
[21]	Tal-Singer R, Crapo JD. COPD at the Time of COVID-19: A COPD Foundation Perspective[J]. Chronic Obstr Pulm Dis, 2020, 7(2):73-75. doi:10.15326/jcopdf.7.2.2020.0149pmid:32324976
[22]	Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China[J]. N Engl J Med, 2020, 382(18):1708-1720. doi:10.1056/NEJMoa2002032 URL
[23]	Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysio-logy, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019(COVID-19): A Review[J]. JAMA, 2020, 324(8):782-793. doi:10.1001/jama.2020.12839pmid:32648899
[24]	Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020[J]. MMWR Morb Mortal Wkly Rep, 2020, 69(30):993-998. doi:10.15585/mmwr.mm6930e1 URL
[25]	Carfì A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19[J]. JAMA, 2020, 324(6):603-605. doi:10.1001/jama.2020.12603 URL
[26]	van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1[J]. N Engl J Med, 2020, 382(16):1564-1567. doi:10.1056/NEJMc2004973 URL
[27]	Demeyer H, Louvaris Z, Frei A, et al. Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial[J]. Thorax, 2017, 72(5):415-423. doi:10.1136/thoraxjnl-2016-209026pmid:28137918
[28]	新型冠状病毒肺炎恢复期中西医结合康复指南(第一版)[J]. 天津中医药, 2020, 37(5):484-489.
	Guidelines for the rehabilitation of novel coronavirus pneumonia in the convalescent period by combining traditional Chinese and Western Medicine (First Edition)[J]. Tianjin Tradit Chin Med, 2020, 37(5):484-489.
[29]	Singanayagam A, Glanville N, Girkin JL, et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations[J]. Nat Commun, 2018, 9(1):2229. doi:10.1038/s41467-018-04574-1pmid:29884817
[30]	Finney LJ, Glanville N, Farne H, et al. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon[J]. J Allergy Clin Immunol, 2021, 147(2):510-519. doi:10.1016/j.jaci.2020.09.034pmid:33068560
[31]	Yamaya M, Nishimura H, Deng X, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells[J]. Respir Investig, 2020, 58(3):155-168. doi:10.1016/j.resinv.2019.12.005 URL
[32]	Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective[J]. Eur Respir J, 2020, 55(5):2001009.
[33]	Schultze A, Walker AJ, MacKenna B, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform[J]. Lancet Respir Med, 2020, 8(11):1106-1120. doi:10.1016/S2213-2600(20)30415-Xpmid:32979987
[34]	Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic[J]. J Am Coll Cardiol, 2020, 75(18):2352-2371. doi:S0735-1097(20)34637-4pmid:32201335
[35]	Couturaud F, Bertoletti L, Pastre J, et al. Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms[J]. JAMA, 2021, 325(1):59-68. doi:10.1001/jama.2020.23567pmid:33399840
[36]	Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis[J]. J Med Virol, 2020, 92(10):1915-1921.
[37]	Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence[J]. Tob Induc Dis, 2020, 18:20.

新型冠状病毒疫情时期的慢性阻塞性肺疾病管理策略——2022版慢性阻塞性肺疾病全球倡议解读

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献37

相关文章15

编辑推荐

Metrics

本文评价

[1]	石峰, 郭竹英, 郭海艳.新型冠状病毒肺炎患者外周血淋巴细胞亚群变化的临床意义[J]. 诊断学理论与实践, 2022, 21(05): 619-624.
[2]	陈沁, 徐雯莉, 丰青, 陈瑜, 邓雪芹, 陈芸, 庞碧芸.新型冠状病毒肺炎收治定点医院护理人力资源的调配与实践[J]. 诊断学理论与实践, 2022, 21(02): 273-276.
[3]	张红, 朱梦梦.新型冠状病毒肺炎疫情期间老年人进食安全护理[J]. 诊断学理论与实践, 2022, 21(02): 277-280.
[4]	梁婧, 黄晨, 蒋琰, 许敬华, 梁晓虹, 杨之涛, 景峰.新冠疫情下急诊输液室的护理防控管理策略[J]. 诊断学理论与实践, 2022, 21(02): 281-285.
[5]	开云网页登录医学院附属瑞金医院新冠诊治专家组.新型冠状病毒奥密克戎变异株感染合并严重基础疾病的救治[J]. 诊断学理论与实践, 2022, 21(02): 105-117.
[6]	新冠病毒定点医院公共学科工作模式撰写组.开云网页登录医学院附属瑞金医院抗击新型冠状病毒定点医院公共学科工作模式[J]. 诊断学理论与实践, 2022, 21(02): 118-127.
[7]	中华医学会内分泌学分会.新型冠状病毒肺炎疫情下甲状腺功能亢进症和甲状腺功能减退症管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 128-129.
[8]	中华医学会内分泌学分会.新型冠状病毒肺炎疫情下垂体疾病管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 130-132.
[9]	中华医学会内分泌学分会.新型冠状病毒肺炎疫情下骨质疏松症管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 133-135.
[10]	中华医学会内分泌学分会.新型冠状病毒肺炎疫情下糖尿病管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 136-138.
[11]	中华医学会内分泌学分会.新型冠状病毒肺炎疫情下肾上腺疾病管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 139-142.
[12]	陈长强, 孟俊, 金佩佩, 戴菁.定点医院新型冠状病毒肺炎患者核酸检测工作的实践和探索[J]. 诊断学理论与实践, 2022, 21(02): 143-149.
[13]	庄蕾, 郑睿智, 高卫益.某独栋办公楼内新型冠状病毒奥密克戎株聚集性疫情分析[J]. 诊断学理论与实践, 2022, 21(02): 150-153.
[14]	张祎博, 吴文娟, 毕宇芳, 景峰, 顾志冬, 杨之涛, 尚寒冰, 林靖生, 陈尔真.大型方舱医院感染预防与控制体系的建设和实践探索[J]. 诊断学理论与实践, 2022, 21(02): 165-168.
[15]	丁宁, 陈诗恺, 孟俊, 戴菁, 金佩佩.新型冠状病毒奥密克戎株核酸检测循环阈值与感染患者转阴周期的相关性及影响因素分析[J]. 诊断学理论与实践, 2022, 21(02): 169-173.